Upgrade to SI Premium - Free Trial

AstraZeneca (AZN): PT Rises To $40 On Solid Quarter - BMO

February 5, 2018 6:22 AM
BMO Capital analyst, Alex Arfaei, reiterated his Outperform rating on shares of AstraZeneca (NYSE: AZN) and raised his price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles